Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 22
U.S. Biotech Industry Analysis
UpdatedAug 22, 2024
DataAggregated Company Financials
Companies555
- 7D4.7%
- 3M7.3%
- 1Y15.1%
- YTD7.1%
In the last week, the Biotech industry is up 4.7%, with AbbVie up 1.8%. This takes the industry's 12 month performance to a gain of 15%. Earnings are forecast to grow by 30% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 22 Aug 2024 | US$903.8b | US$113.2b | -US$35,868,195,932.56 | 23.3x | -25.2x | 8x |
| Sat, 20 Jul 2024 | US$1.2t | US$164.5b | -US$28,047,850,966.89 | 29x | -42.5x | 7.3x |
| Mon, 17 Jun 2024 | US$1.2t | US$164.4b | -US$27,941,797,208.37 | 27.3x | -41.4x | 7x |
| Wed, 15 May 2024 | US$1.1t | US$164.6b | -US$27,141,970,719.54 | 27.5x | -41.5x | 6.8x |
| Fri, 12 Apr 2024 | US$1.1t | US$164.3b | -US$23,380,537,394.48 | 21x | -48x | 6.8x |
| Sun, 10 Mar 2024 | US$1.2t | US$167.3b | -US$22,140,783,177.03 | 19x | -53.9x | 7.1x |
| Tue, 06 Feb 2024 | US$1.3t | US$196.1b | -US$18,610,955,456.92 | 17.5x | -70.8x | 6.7x |
| Thu, 04 Jan 2024 | US$1.4t | US$204.8b | -US$22,306,519,032.00 | 20.9x | -63.4x | 6.9x |
| Sat, 02 Dec 2023 | US$1.3t | US$204.7b | -US$22,044,035,456.00 | 19x | -56.7x | 6.1x |
| Mon, 30 Oct 2023 | US$1.2t | US$206.6b | -US$15,116,353,891.00 | 16.3x | -78x | 5.7x |
| Wed, 27 Sep 2023 | US$1.3t | US$207.4b | -US$12,903,835,924.00 | 17.2x | -98.3x | 6.1x |
| Fri, 25 Aug 2023 | US$1.3t | US$207.6b | -US$12,461,259,012.00 | 17.3x | -102.1x | 6.1x |
| Sun, 23 Jul 2023 | US$1.2t | US$186.6b | -US$16,026,393,300.00 | 12.8x | -72x | 6.2x |
| Tue, 20 Jun 2023 | US$1.2t | US$186.3b | -US$16,029,005,553.00 | 12.1x | -72.4x | 6.2x |
| Thu, 18 May 2023 | US$1.1t | US$186.1b | -US$15,822,861,311.00 | 13.3x | -72.4x | 6.2x |
| Sat, 15 Apr 2023 | US$1.2t | US$198.5b | -US$3,247,497,685.00 | 14.1x | -361.6x | 5.9x |
| Mon, 13 Mar 2023 | US$1.1t | US$199.3b | -US$4,753,099,202.00 | 14.9x | -230.1x | 5.5x |
| Wed, 08 Feb 2023 | US$1.2t | US$202.3b | US$1.4b | 16.5x | 806.8x | 5.8x |
| Fri, 06 Jan 2023 | US$1.2t | US$203.1b | US$1.5b | 14.4x | 751.8x | 5.7x |
| Sun, 04 Dec 2022 | US$1.2t | US$202.6b | US$1.4b | 15.1x | 842.2x | 5.8x |
| Tue, 01 Nov 2022 | US$1.1t | US$205.8b | US$7.3b | 14.2x | 148.4x | 5.3x |
| Thu, 29 Sep 2022 | US$1.1t | US$205.8b | US$5.6b | 15.1x | 187.7x | 5.1x |
| Sat, 27 Aug 2022 | US$1.0t | US$206.2b | US$7.3b | 15.2x | 143x | 5x |
| Mon, 25 Jul 2022 | US$1.1t | US$211.4b | US$11.3b | 15.8x | 94.4x | 5x |
| Wed, 22 Jun 2022 | US$979.8b | US$212.4b | US$11.0b | 15.1x | 88.7x | 4.6x |
| Fri, 20 May 2022 | US$997.1b | US$212.4b | US$10.8b | 14.9x | 92.2x | 4.7x |
| Sun, 17 Apr 2022 | US$1.3t | US$226.7b | US$14.7b | 18.7x | 86.6x | 5.6x |
| Tue, 15 Mar 2022 | US$1.2t | US$222.2b | US$10.5b | 18.5x | 113.8x | 5.4x |
| Thu, 10 Feb 2022 | US$1.3t | US$216.4b | US$6.9b | 21.9x | 187.6x | 6x |
| Sat, 08 Jan 2022 | US$1.3t | US$212.0b | US$2.7b | 25x | 496.1x | 6.3x |
| Mon, 06 Dec 2021 | US$1.4t | US$211.9b | US$3.1b | 25.1x | 460.6x | 6.6x |
| Wed, 03 Nov 2021 | US$1.5t | US$196.8b | -US$3,053,863,208.00 | 25.2x | -499.6x | 7.8x |
| Fri, 01 Oct 2021 | US$1.5t | US$196.3b | -US$2,491,168,411.00 | 25.1x | -610.1x | 7.7x |
| Sun, 29 Aug 2021 | US$1.6t | US$197.0b | -US$1,734,385,785.58 | 22x | -917.7x | 8.1x |
Price to Earnings Ratio
-917.7x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 8.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 17% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 3.13% | |
| Healthcare | 2.44% | |
| Biotech | 4.70% | |
| Biotech | 4.70% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$196.53 | 1.8% +US$6.2b | 33.6% | PE65.5x | |
| VRTX Vertex Pharmaceuticals | US$486.11 | 3.0% +US$3.6b | 40.2% | PS12.1x | |
| AMGN Amgen | US$329.15 | 2.0% +US$3.4b | 27.9% | PE56.5x | |
| REGN Regeneron Pharmaceuticals | US$1.19k | 2.5% +US$3.1b | 41.0% | PE29.6x | |
| ALNY Alnylam Pharmaceuticals | US$279.17 | 6.2% +US$2.1b | 46.6% | PS15.3x |
